[1]Hunt, J. E. and D. E. Cooke, (1996). , "Learning using an artificial immune system, " Journal of Network and Computer Applications, Vol. 19, pp. 189-212.
[2]Bross, I. D. (1966). Spurious effects from an extraneous variable. Journal of chronic diseases, 19(6), pp. 637-647.
[3]Bombardier, C., Laine, L., Reicin, A., Reicin A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, D.,Fe1Taz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., and Schnitzer, T.J. (2000), "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid artluitis," The New England Journal of Medicine, 343, pp. 1520-1528.
[4]Brookhart, M.A., Schneeweiss, S., Rotlunan, K.J., Glynn, R.J., Avorn, J., and StUrmer, T. (2006),"Variable selection for propensity score models," American Journal of Epidemiology, 163(12),pp.1149-1156.
[5]Carpenter, J., and Bithell, J. (2000), "Bootstrap confidence intervals: when, which, and what?," Statistics in Medicine, 19, pp. 1141-1164.
[6]Chen, T. C. (2006). IAs based approach for reliability redundancy allocation problems. Applied Mathematics and Computation, 182(2), 1556-1567.
[7]Chen, T.-C. and Hsieh, Y.-C. (2008), "Use of immune based GA for the periodic marketing problems," Mathematical and Computer Modeling, 48(3-4), pp. 420-428.
[8]Concato, J., Shah, N., and Horwitz, R.I. (2009), "Randomized, controlled trials, observational studies, and the hierarchy of research designs," New England Journal of Medicine, 342, pp.1887-92.
[9]Ye, Y., Kaskutas, L. A. (2009). Using propensity scores to adjust for selection bias when assessing the effectiveness of Alcoholics Anonymous in observational studies. Drug and alcohol dependence, 104(1), pp. 56-64.
[10]Cochran, W. G. (1968). The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics, 295-313.
[11]Cox, E., Martin, B. C., Van Staa, T., Garbe, E., Siebert, U., & Johnson, M. L. (2009). Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II.Value in Health, 12(8), 1053-1061.
[12]D'' Agostino, R.B. Jr. (1998), "Propensity score methods for bias reduction n the comparison of a treatment to a non-randomized control group," Statistics in Medicine, 17, pp. 2265-2281.
[13]De Castro, L.N and Von Zuben, F.J. (2000), "The clonal selection algorithm with engineering applications," In Workshop Proceedings of the GECCO 2000, Las Vegas, USA, pp. 36-37.
[14]FDA Statement (November 17, 2004) For inunediate release FDA Statement on Vioxx and Recent Allegations and the Agency''s Continued Commitment to Sound Science and Peer Review. Available from: http://wwwfda.gov/bbs/topics/news/2004/NEWO1136.html
[15]Freedman, D.A., Navidi, W., Peters, S.C. (1988), "On the impact of variable selection in fitting regression equations," In: Dijlestra, TK., editor. On model uncertainty and its statistical implications. Berlin, Germany, Springer, pp. 1-16.
[16]Gail, M.H., Wieand, S., Piantadosi, S., (1984), "Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariate," Biometrika, 71 (3), pp. 431-444.
[17]Garbe, E., KLoss, S., Suling, M., Pigeot, I., and Sclmeeweiss, S. (2013), "Bight-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications," Pharmacoepidemiology and Prescription, 69, pp. 549-557.
[18]Hirano, K. and Imbens, G.W. (2001), "Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization," Health Services and Outcomes Research Methodology, 2, pp. 259-278.
[19]Institute of Medicine (US) Roundtable on Value & Science-Driven Health Care (2011), "Learning What Works: Infrastmcture Required for Comparative Effectiveness Research: Workshop Summary," in Appendix C Comparative Effectiveness Research Priorities: 10M Recommendations (2009)" Washington (DC): National Academies Press (US).
[20]Jerne, N.K. (1973), "The immune system," Scientific America, 229(1), pp. 52-60.
[21]Johnson, M.L., Crown, W., Martin, B.C., Dormuth, C.R., and Siebeti, U. (2009), "Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III," Value Health, 12(8), pp.l 062-1073.
[22]Michalewicz, Z. (1996), Genetic Algorithms + Data Structures = Evolution Programs, 3rd Edition, Springer-Verlag Berlin Heidelberg, NY.
[23]Rassen, J.A., Glynn, R.J., Brookhart, M.A., and Schneeweiss, S. (2013), "Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples," American Journal of Epidemiology, 173(12), pp.l404-1413.
[24]Rassen, J. A., & Schneeweiss, S. (2012). Using high‐dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiology and drug safety, 21(S1), 41-49.
[25]Rosenbaum, P.R., Rubin, D.B. (1983), "The central role of the propensity score in observational studies for causal effects," Biometrika, 70 (1), pp. 41 -55.
[26]Rubin, D.B. (2007), "The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials," Statistics in medicine, 26(1), pp. 20-36.
[27]Rubin, D.B. (1997), "Estimating causal effects from large data sets using propensity score," Atmals of Internal Medicine, 127(8 Pt 2), pp. 757-763.
[28]Rubin, D.B., and Thomas, N. (1996), "Matching using estimated propensity score: relating theory to practice," Biometrics, 1996, 52, pp. 249-264.
[29]Sclmeeweiss, S. (2007), "Developments in post-marketing comparative effectiveness research," Clinical Pharmacology & Therapeutics, 82(2), pp. 143-156.
[30]Schneeweiss, S., and Avorn, J. (2005), "A review of use of health care utilization databases for epidemiclogic research on therapeutics," Journal of Ciinical Epidemiology, 58(4), pp. 323-337.
[31]Schneeweiss, S., Patrick, A.R., Solomon, D.H., Mehta, J., Dormuth, C., Miller, M., Lee, J.C., Wang, P.S. (2010), "Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years'' data," Archives of General Psychiat1y, 67(5), pp. 497-506.
[32]Schneeweiss, S., Rassen, J.A., Glynn, R.J., Avorn, J., Mogun, H., and Brookhart M.A. (2009), "High-dimensional propensity score adjustment in studies of treatment effects using health care claims," Epidemiology, 20(4), pp. 512-522.
[33]Sclmeeweiss, S., Solomon, D.H., Wang, P.S., Rassen, J., Brookhart, M.A. (2006), "Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory dmgs: an instmmental variable analysis," Arthritis & Rheumatism, 54(11), pp. 3390-2298.
[34]Solomon, D.H., Rassen, J.A., Glynn, R.J., Lee, J., Levin, R., Schneeweiss, S. (201 0), "The comparative safety of analgesics in older adults with atihritis," Archives of Internal Medicine, 170(22), pp. 1968-1976.
[35]Topol, E.J. (2004), "Failing the Public Health- Rofecoxib, Merck, and the FDA," New England Journal of Medicine, 351, pp.l707-1709.
[36]Toh, S.T., Garcia Rodriguez, L.A., and Hernan, M.A. (2011), "Confounding adjustment via a semi-automated high-dimensional propensity score algoritlun: An application using electronic medical record data," Pharmacoepidemiology and Drug Safety, 20(8), pp. 849-857.
[37]Walker, A.M. (1996), "Confounding by indication," Epidemiology, 7, pp. 335-336.
[38]Huck, S. W., Cormier, W. H., & Bounds, W. G. (1974). Reading statistics and research (pp. 74-102). New York: Harper & Row.
[39]Viera, A. J. (2008). "Odds ratios and risk ratios: what’s the difference and why does it matter?. Southern medical journal, " 101(7), 730-734.
[40]Ilmari, Karonen. (2006). Clonal selection, http://en.wikipedia.org
[41]Frawley, W. J., Piatetsky-Shapiro, G., & Matheus, C. J. (1992). "Knowledge discovery in databases: An overview," AI magazine, 13(3), 57.
[42]Reinschmidt, J., Gottschalk, H., Kim, H., & Zwietering, D. (1999). Intelligent miner for data: Enhance your business intelligence. IBM Corporation.
[43]Neugebauer, R., Schmittdiel, J.A., Zhu, Z., Rassen, J.A., Seeger, J.D., Schneeweiss, S. (2012). "High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions," Statistics in Medicine, pp. 1-25.
[44]廖子銘,2001,“類免疫演算法於多目標最佳化問題之研究與應用”,大同大學機械工程研究所,碩士論文。[45]陳靜慧,2003,“應用類免疫演算法於串並聯系統複製分配最佳化問題之研究”,長榮大學經營管理研究所,碩士論文。[46]鄧宏安,2003,“整合CFDRC及類免疫演算法於散熱片之最佳化設計”,大同大學機械工程研究所,碩士論文。[47]古志強,2004,“運用分散式類免疫演算法於多值域結構拓樸最佳化”,大同大學機械工程研究所,碩士論文。[48]曹惠鈴,2007,“運用混合式進化演算法於法則探勘之回應模型”,國立虎尾科大資料管理系,碩士論文。[49]江泰緯,2008,“以網格運算為基礎進化式演算法於資料探勘分類反應模型建立之研究”,國立虎尾科技大學資訊管理系碩士論文。[50]尤婷藝,2010,“混合式進化演算法於微陣列資料分類法則探勘之研究”,國立虎尾科技大學資訊管理系碩士論文。[51]康廷數位,2011,.NET網路與I/O技術手冊第二版,新北市:松崗。
[52]醫學教育部馬偕紀念醫院,2013,實證醫學相關名詞,http://www.mmh.org.tw/taitam/medical_edu/www/?contentID=644